Skip to main content
European Commission logo print header

Article Category

Content archived on 2023-04-12

Article available in the following languages:

EN

Fighting Haemophilia A: Video Interview with the HemAcure Project Coordinator

The bleeding disease haemophilia A is caused by a genetic deficiency in clotting factor VIII (FVIII). The H2020 funded HemAcure research project is developing a novel cell based therapy to treat severe forms of this disease.

Health icon Health

http://www.hemacure.eu/news/coordinator-video/ Currently, the therapies for treating haemophilia A mainly involve the application of recombinant factor VIII (rFVIII) which implies that patients need regular infusions with this factor. Thus, the HemAcure project is aiming for a permanent solution by developing a novel cell based therapy to treat severe forms of haemophilia A. This new approach will significantly improve the quality of life of haemophilia A patients and reduce the side effects of the disease. Yet, what are the reasons for this disease and what is so special about the innovative approach followed by HemAcure? These and more questions are answered in an interview with the project coordinator Dr. Joris Braspenning (University Hospital Würzburg). More about HemAcure: Webpage: https://web.archive.org/web/20190114014604/https://www.hemacure.eu/ Twitter: https://twitter.com/HemAcure_EU

Keywords

Haemophilia A, Cell based Therapy, ATMP, HemAcure, BOECs, Gene Therapy